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A B S T R A C T
Epigenetic agents such as histone deacetylase (HDAC) inhibitors are widely investigated for use in combined
anticancer therapy and the co-administration of Pt drugs with HDAC inhibitors has shown promise for the
treatment of resistant cancers. Coordination of an HDAC inhibitor to an axial position of a Pt(IV) derivative of
cisplatin allows the combination of the epigenetic drug and the Pt chemotherapeutic into a single molecule. In
this work we carry out mechanistic studies on the known Pt(IV) complex cis,cis,trans-[Pt(NH3)2Cl2(PBA)2] (B)
with the HDAC inhibitor 4-phenylbutyrate (PBA) and its derivatives cis,cis,trans-[Pt(NH3)2Cl2(PBA)(OH)] (A),
cis,cis,trans-[Pt(NH3)2Cl2(PBA)(Bz)] (C), and cis,cis,trans-[Pt(NH3)2Cl2(PBA)(Suc)] (D) (Bz = benzoate,
Suc = succinate). The comparison of the cytotoxicity, effect on HDAC activity, reactive oxygen species (ROS)
generation, γ-H2AX (histone 2A-family member X) foci generation and induction of apoptosis in cisplatin-sen-
sitive and cisplatin-resistant ovarian cancer cells shows that A – C exhibit multimodal mechanisms involving
DNA damage and apoptosis independent of cisplatin resistance.
1. Introduction
Cisplatin (cis-[Pt(NH3)2Cl2]) has been used as a chemotherapeutic
cancer drug since 1978, specifically in the treatment of testicular, head
and neck, bladder and ovarian carcinomas [1]. The generally accepted
mode of action of cisplatin involves covalent binding of the cis-Pt
(NH3)22+ entity to adjacent guanine bases in DNA following loss of the
chlorido leaving group ligands. The formation of these DNA lesions
triggers the DNA damage response by activating or silencing various
genes. If the damage is beyond repair, mitochondrial apoptosis is in-
itiated [2,3].
Inherent and acquired resistance towards platinum drugs presents a
major clinical challenge and a significant limitation of platinum-based
chemotherapy [4]. Cisplatin resistance is the consequence of genetic
and epigenetic changes that lead to decreased cellular uptake, increased
cellular efflux, detoxification due to increased glutathione or thior-
edoxin levels, enhanced DNA repair, enhanced DNA damage tolerance
and late apoptotic response [5]. The main types of epigenetic altera-
tions in general are DNA methylation and histone methylation or
acetylation [6]. Histone acetylation and deacetylation regulate gene
expression by opening (acetylation) and closing (deacetylation) the
chromatin [7]. Histone acetylation has a critical regulatory function in
DNA repair and recent studies suggest that it plays a role in the de-
velopment of drug resistance [4]. Histone acetylation and deacetylation
are catalyzed by histone acetyltransferase (HAT) and histone deacety-
lase (HDAC) respectively.
The combination of epigenetic drugs with conventional che-
motherapy shows significant promise as a strategy for the treatment of
resistant cancers [8]. Several HDAC inhibitors (HDACis) have entered
clinical trials [9,10] and the first HDACi was approved by the FDA in
2006 [11]. Several studies have shown that the co-administration of
cisplatin with an HDACi leads to enhanced therapeutic efficacies
[12–14]. Belinostat in combination with cisplatin reverses resistance in
Pt-resistant lung cancer cells [15]. Trichostatin A has an additive effect
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with oxaliplatin in gastric tumor cells [16]. Pt-resistant ovarian cancer
cells are sensitized to cisplatin-mediated cell death when pre-treated
with HDAC and methylation inhibitors [17].
While different pharmacokinetics can be a problem in co-adminis-
tration, coordination of the HDACi to the Pt centre ensures the si-
multaneous delivery of both drugs. Marmion and coworkers developed
Pt(II) complexes in which a functionalized HDAC inhibitor ligand is
coordinated to the trans-Pt(NH3)(py)2+, trans-Pt(py)22+ (py = pyr-
idine) [18] or cis-Pt(NH3)22+ entity [19–21]. Kasparkova et al. reported
a photoactivatable Pt(IV) complex of the HDAC inhibitor suberoyl-bis-
hydroxamic acid [22]. Gibson and coworkers and Brabec and cow-
orkers attached the HDACis 4-phenylbutyrate (PBA) and valproate
(VPA) to the axial positions of Pt(IV) derivatives of cisplatin, oxaliplatin
and [Pt(1S,2Sdiaminocyclohexane)(5,6-dimethyl-1,10-phenanthro-
line)]2+ [23–27]. Pt(IV) complexes are pro-drugs that release the active
Pt(II) drug and the axial ligands on intracellular reduction. The bis-PBA
complex cis,cis,trans-[Pt(NH3)2Cl2(PBA)2] showed an up to 100-fold
higher cytotoxicity than cisplatin and significant HDAC inhibition ac-
tivity suggesting a synergism between Pt and PBA [27]. The Pt(IV)
complex cis,cis,trans-[Pt(NH3)2Cl2(VPA)2] with the HDACi valproate
was studied by Osella and coworkers [28], Shen and coworkers [29]
and Gibson and coworkers [27]. Very recently, the same researchers
reported a triple-action Pt(IV) complex containing PBA and a second
epigenetically acting ligand, octanoate [24,30]. As part of our own
work we have recently reported Pt(IV) derivatives of carboplatin with
an axial PBA ligand and a second biologically inactive carboxylate li-
gand to modify the lipophilicity [31].
We compare here the DNA damage, reactive oxygen species (ROS)
generation, HDAC activity and induction of apoptosis in cisplatin-sensi-
tive A2780 and cisplatin-resistant A2780cis cells on treatment with the
known Pt(IV) complex cis,cis,trans-[Pt(NH3)2Cl2(PBA)2] and its deriva-
tives cis,cis,trans-[Pt(NH3)2Cl2(PBA)(OH)], cis,cis,trans-[Pt(NH3)2Cl2(PBA)
(Bz)], and cis,cis,trans-[Pt(NH3)2Cl2(PBA)(Suc)] (Bz = benzoate,
Suc = succinate) in order to provide more insight into the ability of Pt(IV)
PBA pro-drugs to overcome cisplatin resistance in ovarian cancer cells.
2. Experimental
2.1. Syntheses
The syntheses of the Pt(IV) complexes is described in the
Supplementary Material.
2.2. Measurements and instrumentation
1H and 195Pt nuclear magnetic resonance (NMR) spectra were re-
corded with a Varian 500 AR spectrometer. Chemical shifts are given in
parts per million (ppm) with tetramethylsilane as the reference (δ (1H
NMR) = 0 ppm). Coupling constants (J) are given in Hertz (Hz). 195Pt
NMR spectra were acquired in dimethylformamide (DMF) with an in-
serted tube containing D2O. K2PtCl6 in D2O was used as an external
reference. Mass spectra were obtained with a Waters LCT Premiere XE
with electron spray ionization (ESI) and time of flight mass analyzer.
Elemental analyses (carbon, nitrogen and hydrogen) were carried out
with a PerkinElmer 2400 series II analyzer. Pt concentrations were
measured by inductively coupled plasma mass spectrometry (ICP-MS,
ELAN DRCe, PerkinElmer, Waltham, USA) in a class 1000 cleanroom
[32–35]. The calibration curve was obtained using known concentra-
tions of platinum standard solutions (0–50 μM).
2.3. Stability studies
Complexes A and C were dissolved in 0.5 mL dimethylformamide
and diluted with 0.5 mL acetonitrile and 3 mL physiological saline
(0.9% NaCl) to a final concentration of 6 and 4 mM, respectively. The
samples were kept at 37°C for 72 h and analyzed at regular intervals by
high-performance liquid chromatography (HPLC; Agilent 1200,
Phenomenex Luna C18 column, 5 μm, 100 Å, 250 mm× 4.60 mm i.d.).
The mobile phase was 70:30 acetonitrile (1% trifluoroacetic acid):
water (1% trifluoroacetic acid).
2.4. Monitoring of the reduction of the Pt(IV) complexes by HPLC
The reduction of complexes A and C was monitored using an Agilent
1200 series diode array detector analytical HPLC instrument. The
compounds were dissolved in 0.5 mL dimethylformamide, added to a
7 mM solution of ascorbic acid in 4 mM 4-(2-hydroxyethyl)piperazine-
1-ethanesulfonic acid (HEPES) buffer (pH 7) and diluted with acet-
onitrile to a final concentration of 0.5 mM. The reduction was mon-
itored at 37 °C until completion. The samples were analyzed using a
Phenomenex Luna C18 column (5 μm, 100 Å, 250 mm× 4.60 mm i.d.).
The mobile phase was 90: 10 acetonitrile (1% trifluoroacetic acid):
water (1% trifluoroacetic acid). The flow rate was 1.0 mL min−1 and
the fractions were detected at 254 nm.
2.5. Determination of lipophilicity
Octanol-water partition coefficients (logPo/w) of the Pt(IV) com-
pounds were determined by the shake flask method (Test No. 107:
Partition Coefficient (n-Octanol/Water): Shake Flask Method;
Organisation for Economic Co-operation and Development: Paris
(1995)). All experiments were done in duplicate. The respective Pt(IV)
complex was mixed with 0.9% NaCl (w/v) in ultrapure water that was
presaturated with n-octanol for 3 d. All solutions were sonicated and
filtered to remove undissolved Pt(IV) compound. The initial Pt con-
centrations were measured by ICP-MS as described above.
Subsequently, the Pt(IV) solution was added to an equal volume of n-
octanol that was presaturated with 0.9% NaCl (w/v) in ultrapure water
containing 1% HNO3. The heterogeneous mixture was shaken vigor-
ously for 1 h before centrifuging at 4400 rpm for 1 h to achieve phase
separation. The final Pt concentration in the aqueous phase was mea-
sured again by ICP-MS. LogPo/w values were calculated as the ratio of Pt
concentrations in the organic and aqueous phases.
2.6. Experiments with cultured human cells
The tested compounds (A – D) were dissolved in dimethyl sulfoxide
(DMSO, Merck, Germany) before the start of the experiment. The final
concentration of DMSO was ≤0.3%. A2780 and A2780cis cells were
obtained commercially from European Collection of Authenticated Cell
Cultures (ECACC) (Public Health England, UK). Cells were grown in
Roswell Park Memorial Institute (RPMI - 1640) medium (Sigma,
Ireland) supplemented with 12% Fetal Bovine Serum (Sigma, Ireland)
and 5% L-glutamine (Sigma, Ireland) and incubated at 37 °C in 5% CO2.
A sub-lethal dose of 1 μM cisplatin was added to A2780cis cells to
maintain cisplatin resistance. Stock cells were grown to 80–90% con-
fluence and were then trypsinised to generate a cell suspension for
experimental use.
2.7. Cell viability
Cellular viability was evaluated by the MTT (3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma, Ireland)
assay which is a colorimetric assay that measures the metabolic activity
of cells [36]. The ovarian adenocarcinoma cell lines were plated in 96-
well plates with a total number of 1 × 104 cells/well and 8 × 103 cells/
well for 24 and 48 h, respectively for each cell line, and the plates were
incubated at 37 °C for 24 h for attachment and growth. Cells were then
treated with different concentrations of the test compounds (2.5 μM –
200 μM) in triplicate and a solvent control (0.3% DMSO) for 24 and
48 h timepoints. The cell culture medium and test drug was discarded
from the plate wells and 100 μL of a solution of MTT (5 mg / mL) was
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added to each well. The cells were incubated for 3 h and washed three
times with sterilised PBS. 100 μL of DMSO was added to each well and
plates were shaken gently for 15 min to dissolve the coloured formazan
crystals formed by cellular nicotinamide adenine dinucleotide phos-
phate (NADPH) dependent oxidoreductase enzymes. The absorbance at
595 nm of each well was measured using a microplate reader and a
1420 Multilabel Counter Victor3V spectrophotometer (PerkinElmer,
USA). All MTT assays were performed in triplicate at three independent
times with six replicate wells for each test compound. For statistical
analysis, the mean and standard deviation was calculated using Mi-
crosoft® Excel (Microsoft Corporation, USA). The calculations of the
IC50 concentrations for each cell line, timepoint, complex and control
was performed using the statistical package GraphPad Prism (Ver. 6.0)
(GraphPad, USA). The IC50 value is the concentration of the test com-
pounds that reduces the cellular viability by 50%.
2.8. Reactive oxygen species (ROS) assay
The induction of intracellular oxidative stress in A2780 and
A2780cis cells was measured using a 2′,7′-dichlorofluorescein diacetate
(DCFH-DA) dye which produces fluorescence on the production of re-
active oxygen species. Briefly, cells were seeded into 96-well plates at a
density of 1 × 104 cells/well and were incubated for 24 h at 37 °C. The
medium was removed and 100 μL of a 20 μM DCFH-DA solution in PBS
was added to each well and incubated at 37 °C and 5% CO2 for 60 min
in darkness. Cells were washed twice with 100 μL PBS and then treated
with 100 μL of 10 μM H2O2 in PBS (positive control), with PBS alone
(untreated control) and a concentration range of 0.47–60 μM of each
test compound. The fluorescence was measured at different time in-
tervals between 15 and 120 min. ROS levels were determined by
measuring the fluorescence of oxidized DCFH-DA using a spectramax
M3 multiplate reader with excitation at 485 nm and emission at
530 nm. Three independent experiments were done with six replicate
wells used for all test compounds, positive control and untreated con-
trol.
2.9. Cellular uptake
1 × 106 A2780 cells were seeded in T25 cm2 flasks in growth
medium (5 mL). After overnight incubation the medium was replaced
and the cells were treated with IC50 concentrations of the tested com-
pounds for 24 h. The cells were washed twice with cold PBS, harvested
by trypsinization and counted using a hemocytometer. The cells were
vortexed vigorously, frozen at −80 °C, treated with 200 μL of highly
pure nitric acid (Trace Metal Grade, 67–69%, Fisher, UK) and trans-
ferred into microwave tubes. The tubes were heated at 80 °C in order to
digest the cells. After cooling, the samples were diluted with ultrapure
water to a final concentration of 1% HNO3. Each mineralized sample
was filtered and the platinum content was analyzed by ICP-MS as de-
scribed above.
2.10. Platination of cellular DNA
A2780 cells (0.8 × 106) were seeded in 9 cm2 6-well culture plates
in 5 mL of RPMI1640 cell culture medium. After overnight incubation,
the medium was replaced, and the cells were treated with IC50 con-
centrations of the tested compounds for 24 h. The cells were washed
twice with cold PBS, harvested by trypsinization and counted using a
hemocytometer. The cells were stored at −80 °C until analysis. The
DNA was extracted and purified by using a cell lysis buffer (2.5% Triton
X-100, 100 mM Tris-HCl pH 8, 10 mM ethylenediaminetetraacetate, 2%
sodium dodecyl sulfate, 200 mM NaCl, 200 μg mL−1 proteinase K) and
incubated for 2 h at 56 °C. 6 μL of RNAse A solution (0.4 mg mL−1) was
added and samples were incubated at room temperature for 1 h.
1000 μL of 2-propanol was added to each sample in order to precipitate
the DNA. The samples were stored overnight at −20 °C. The DNA was
isolated by centrifugation at 18000 ×g for 30 min at 4 °C. Then the
DNA pellet was washed with 70% ethanol. The DNA was dissolved in
200 μL of nuclease-free water and the DNA concentration was de-
termined with a MaestroNano spectrophotometer. The samples were
stored at −20 °C until analysis. The DNA samples were dried using a
freeze dryer and 300 μL of high purity concentrated HNO3 was added to
all samples. The DNA samples were transferred to borosilicate glass
microwave tubes. After heating at 80 °C for 2 h to digest the samples,
they were diluted with 1% HNO3 in ultrapure water. The samples were
filtered and analyzed by ICP-MS as described above.
2.11. Determination of DNA double-strand breaks (DSBs)
The occurrence of DSBs in A2780 and A2780cis cells was quantified
by using immunodetection of γ-H2AX (histone 2A-family member X)
foci by flow cytometry. Cells were seeded at different densities (1 × 104
cells/well and 8 × 103 cells/well for 24 and 48 h, respectively) and
incubated at 37 °C in a humidified, 5% CO2 atmosphere for 24 h. The
cells were exposed to IC50 concentrations of the Pt(IV) complexes, cis-
platin and PBA over the two incubation times, 24 h and 48 h. Then, the
culture medium was removed and the cells were washed with 2 × 4 mL
PBS. The cells were harvested and fixed in 200 μL 2% (v/v) paraf-
ormaldehyde in PBS for 10 min at room temperature. The solution was
removed and 1 mL of cold 95% ethanol was added to fix the cells which
were then stored at 4 °C overnight. The ethanol was removed after
centrifugation at 800 ×g for 5 min and cells were washed once with
PBS and resuspended in 1 mL of 0.25% (v/v) Triton X-100 in PBS for
5 min at room temperature to permeabilise the cells. This was removed
and cells were resuspended in 500 μL of blocking solution (PBS con-
taining 4% fetal bovine serum (FBS)) for 30 min at room temperature.
The primary antibody (Anti-phospho-histone H2A.X (ser139) antibody,
clone JBW301, Mouse, Millipore) was diluted 1:800 with blocking so-
lution and was added to each sample and incubated overnight at 4 °C.
The samples were washed with 500 μL of blocking solution and the
secondary antibody (Alexa Fluor 488 goat anti-mouse immunoglobulin
G (IgG, Invitrogen) was added to the samples for 1 h in the dark.
Samples were washed with 500 μL PBS before analysis. The BD Accuri
C6 (BD Biosciences, USA) flow cytometer was used to detect foci for-
mation in cells staining positive for γ-H2AX fluorescence and was
measured at excitation 495 nm and emission at 519 nm. At least three
independent experiments were conducted for 1 × 104 cells per analysis.
2.12. Immunodetection of γ-H2AX foci with confocal microscopy
Fixed cells were stained with γ-H2AX and propidium iodide as de-
scribed above. 100 μL of cells were aliquoted and deposited on glass
slides by cytospin centrifugation at 1200 rpm for 15 min. Samples were
dried quickly at room temperature for 30 min. Cover slips
(0.085–0.13 mm thick) were mounted on the slides by using mounting
medium and sealed with clear nail varnish. The LSM© 510 Meta
Confocal Microscope (Zeiss, Germany) was used to capture images. The
images were analyzed using ImageJ software. All images were taken at
63× magnification with both argon and helium‑neon lasers simulta-
neously scanning into its four component channels; green (γ-H2AX
foci), red (propidium iodide), merged and brightfield.
2.13. Apoptosis
The induction of apoptosis in A2780 and A2780cis cells was quan-
tified by flow cytometry using annexin V FITC conjugate (BD
Pharmingen™, UK) and propidium iodide (BD Pharmingen™, UK)
staining. Both cell lines were seeded into T25 flasks at different den-
sities for two different incubation times; 1 × 104 cells/well for 24 h and
8 × 103 cells/well for 48 h incubation. After 24 h new medium was
added and the cells were incubated with IC50 doses of the test and re-
ference compounds at 37 °C in a humidified, 5% CO2 atmosphere for 24
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and 48 h. The cells were trypsinised, harvested and centrifuged
(400 ×g for 6 min). The cells were washed twice with cold PBS fol-
lowed by 1× binding buffer (2 ×). The cells were resuspended in 1×
binding buffer at a concentration of 1 × 106 cells/mL and stained with
5 μL of Annexin V FITC for 15 min. Then 5 μL propidium iodide was
added and incubated for 15 mins in the dark. 400 μL of 1× binding
buffer was then added and each sample was analyzed by flow cyto-
metry. At least three independent experiments were conducted for
1 × 104 cells per analysis.
2.14. HDAC activity/inhibition direct assay
Histone deacetylase activity/inhibition was determined using the
EpiQuik™ HDAC Activity/Inhibition Direct Assay Kit (Colorimetric;
Farmingdale, NY). Briefly, A2780 and A2780cis cells were seeded
(1 × 106) in T25 cm2 flasks in growth medium. Cells were treated for
24 h with IC50 concentrations of the tested compounds and then pro-
cessed according to the EpiGentek manufacturer's instructions. The
measurement of HDAC activity was done in nuclear extracts according
to the manufacturer instructions of a Nuclear Extraction Kit (Nucleic
Acid-Free; EpiGentek, Farmingdale, NY). The absorbance was read on a
spectraMax M3 multiplate reader at 450 nm within 2–15 min.
3. Results and discussion
3.1. Synthesis and characterization of the complexes
The chemical structures of the Pt(IV) complexes investigated in this
study are shown in Scheme 1. The monosubstituted complex cis,cis,-
trans-[Pt(NH3)2Cl2(PBA)(OH)] (A) was synthesized by reacting cis,cis,-
trans-[Pt(NH3)2Cl2(OH)2] with 0.8 equivalents of the activated NHS-
ester of PBA in dimethylsulfoxide at 70 °C for 48 h (Scheme S1, Sup-
plementary Material). Reaction of A with benzoic and succinic anhy-
dride in dimethylformamide gave the unsymmetric complexes cis,cis,-
trans-[Pt(NH3)2Cl2(PBA)(Bz)] (C) and cis,cis,trans-[Pt(NH3)2Cl2(PBA)
(Suc)] (D). Benzoate and succinate were attached to the second axial
position in order to vary the lipophilicity. The bis-substituted complex
cis,cis,trans-[Pt(NH3)2Cl2(PBA)2] (B) was previously synthesized by
Gibson and coworkers [27]. The purity and composition of the com-
plexes were confirmed by elemental analysis, HPLC, electrospray ioni-
zation mass spectrometry, and 1H and 195Pt NMR spectroscopy.
The log Po/w values, determined using the shake-flask method, were
found to be −0.12 ± 0.05 (A), 0.16 ± 0.07 (B), 0.08 ± 0.02 (C)
and − 0.14 ± 0.08 (D) and demonstrate that the complexes follow the
expected order of lipophilicity of B > C > A > D.
HPLC analysis of two representative examples of the complexes (A
and C) confirmed that the Pt(IV) prodrugs are stable in physiological
saline (0.9% NaCl) at 37 °C for at least 72 h (Fig. S1). As Pt(IV) pro-
drugs require activation by biological reducing agents, the reduction of
Scheme 1. Chemical structures of complexes A – D.
Fig. 1. HPLC chromatograms of the reaction of C with 10 eq. ascorbic acid at
37 °C and pH 7. (a) t= 0, (b) 3 h, (c) 9 h, (d) 20 h, (e) the free ligand PBA and
(f) the free ligand Bz.
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the monosubstituted complex (A) and of a representative biscarboxy-
lated complex (C) was monitored under physiological conditions (37 °C,
pH 7) in the presence of ascorbic acid using HPLC (Figs. 1 and S2). The
chromatograms show the release of the axial PBA ligand that accom-
panies the conversion of the octahedral Pt(IV) complexes to square-
planar cisplatin. In the case of C both, free PBA and free benzoate were
identified in the chromatograms. A and C were completely reduced
after 48 and 20 h, respectively. The reduction kinetics of Pt(IV) com-
plexes depend on the nature of the axial ligands, the equatorial ligands
and the reducing agent [37]. Complexes with an axial hydroxido ligand
are usually reduced faster by ascorbate than bis-carboxylated com-
plexes, as the OH group can act as a bridging ligand and facilitate the
electron transfer via an inner-sphere mechanism [38]. In the case of
complexes of type cis,cis,trans-[Pt(NH3)2Cl2L2] with two equatorial
chlorido ligands, however, the rate of reduction by ascorbate often
correlates with the reduction potential; L = OH (~ −900 mV) <
L = RCOO− (~ −600 mV) [1,39] and the faster reduction kinetics of
C compared to A are consistent with this.
3.2. Cytotoxicity
The cytotoxic activities of the complexes were evaluated in two
human ovarian carcinoma cells lines, cisplatin-sensitive A2780 and
cisplatin-resistant A2780cis. These isogenic cell lines were selected on
the basis of their matched genetic background which reduces variability
in drug response studies [40]. Chemoresistance has been associated
with epigenetic modifications including histone modifications, and the
A2780 and A2780cis matched pair of cells is widely used in the study of
HDACis [41–43].
The cytotoxicity was determined after incubation for 24 and 48 h
using the tetrazolium based MTT colorimetric assay. For comparison
purposes, the cytotoxicities of cisplatin and of the uncoordinated
HDACi PBA were assessed under the same experimental conditions.
IC50 values were calculated from the growth inhibition curves and are
shown in Table 1. The Pt(IV) complexes displayed dose- and time-de-
pendent cytotoxicities. The IC50 values of A – C are in the low micro-
molar range, while D is only modestly active. In the A2780 cell line, the
cytotoxic activities follow the order C> > B ~ A > cisplatin> >
D. A – D exhibit similar activities in cisplatin-sensitive and -resistant
cells with resistance factors close to 1. The IC50 values of the most ef-
fective complex C were 16- and 37-fold lower than those of cisplatin in
the two cell lines (48 h incubation). A comparison of the IC50 values at
the 24 h and 48 h timepoints shows a decrease by a factor of 4.9–3.3 for
the PBA complexes on prolonged exposure compared to a factor of
about 2 for cisplatin. The delayed cytotoxicity of the Pt(IV) complexes
can be attributed to the requirement for intracellular activation. The
fact that the largest reduction in IC50 (4.9-fold) is observed for A cor-
relates with the slow reduction kinetics of the monocarboxylated
complex (complete reduction within 48 h (A) vs. 20 h (C)). In agree-
ment with the literature [27], free PBA elicited no cytotoxicity at
micromolar concentrations. At physiological pH, the carboxyl group is
deprotonated so that the IC50 value of PBA of> 200 μM may be a
consequence of the hampered cellular uptake of its negatively charged
form. It has been pointed out in the literature that Pt(IV) PBA com-
plexes are not only pro-drugs of the Pt(II) agent but also present pro-
drugs for PBA and this can involve synergistic accumulation [27].
3.3. Cellular uptake and DNA platination
Fig. 2a shows the Pt content in A2780 cells after exposure to IC50
doses of cisplatin and complexes A – D for 24 h. Except for D, the Pt(IV)
complexes accumulate more efficiently than cisplatin in cells. The poor
cellular uptake of D can explain the low cytotoxicity of this complex
and may be attributed to the hydrophilic succinate ligand which would
be negatively charged at pH 7.4. For A – C, however, the uptake
(B < C < A) does not follow the order of increasing lipophilicity
(A < C < B) which has also been reported for other Pt(IV) complexes
[27,44,45].
As the binding to nuclear DNA is considered to be a crucial event in
the cytotoxic action of platinum drugs, the Pt contents of the DNA from
treated cells were also determined. A2780 cells were exposed to IC50
doses of A – D and cisplatin for 24 h and after extraction of the DNA the
Pt concentration was measured by ICP-MS. The results, expressed as ng
Pt per μg of DNA are shown in Fig. 2b. The Pt(IV) complexes gave
higher levels of DNA platination than cisplatin, except for D that does
not enter the cell effectively. It can be assumed that the cellular uptake
and reduction kinetics are important for the DNA platination levels
after 24 h incubation. The DNA platination in cells treated with A and C
is coherent with this, while the high platination levels observed for
complex B are somewhat surprising given its relatively low cellular
accumulation. It might be speculated that the low cellular uptake is
compensated by the strong HDAC inhibitory activity of the complex
(see below) that can lead to a greater accessibility of the DNA by
keeping the chromatin structure open [6]. The IC50 values at the 48 h
timepoint (C> > B, A > cisplatin>D) correlate with the Pt content
in the DNA (C > A > B > cisplatin>D). However, at the 24 h
timepoint, A and B have higher IC50 values than cisplatin despite their
higher DNA platination levels. Apparently, the Pt(IV) complexes take
longer to exert their cytotoxicity.
3.4. Cellular reactive oxygen species production
The induction of cellular reactive oxygen species (ROS) production
by Pt drugs has been discussed in the literature [46]. Kaluderovic et al.
reported enhanced cellular ROS levels in cells treated with tetra-
chlorido Pt(IV) complexes [47]. The redox and mitochondrial stability
can be stressed by treatment with cisplatin due to ROS production
[48,49]. We therefore investigated the generation of ROS in A2780 and
A2780cis cells after incubation with A – D, cisplatin and PBA. ROS
levels were monitored over a 2 h period using 2′,7′-dichlorofluorescein
Table 1
IC50 values of Pt(IV) complexes A – D, cisplatin and free ligand PBA in A2780 and A2780cis cells determined by the MTT test.
IC50 (μM) ± S.D.a R.F.b
A2 780 A2780cis
24 h 48 h 24 h 48 h 24 h 48 h
A 24.2 ± 7.1 4.93 ± 0.19 35.6 ± 11.6 6.3 ± 2.1 1.5 1.3
B 18.4 ± 4.3 4.6 ± 1.3 14.2 ± 2.2 5.1 ± 1.1 0.8 1.1
C 1.8 ± 0.1 0.51 ± 0.16 3.1 ± 1.4 0.71 ± 0.36 1.7 1.4
D 124.1 ± 26.9 38.1 ± 8.5 149.4 ± 36.8 43.2 ± 6.5 1.2 1.1
cisplatin 16.4 ± 5.2 8.3 ± 2.4 55.4 ± 14.1 26.5 ± 4.7 3.4 3.2
PBA > 200 > 200 > 200 > 200 – –
a All MTT assays were performed in triplicate at three independent times with six replicate wells for each test compound.
b R.F. = resistance factor; ratio of IC50 values for A2780 and A2780cis cells.
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diacetate (H2DCFDA) as a peroxide-sensitive fluorescent dye (Figs. 3
and S3). A2780 cells treated with cisplatin, PBA and the Pt(IV) com-
plexes showed a time- and concentration-dependent increase in ROS
production. However, while cisplatin, the free ligand and A and D had
moderate effects only, concentrations of C in the IC50 range resulted in
markedly enhanced ROS levels, comparable to those induced by the
positive control H2O2. There were no significant differences in ROS
generation on treatment with C between the sensitive and resistant cell
line.
3.5. HDAC inhibition
The ability of the three most cytotoxic Pt(IV) pro-drugs to inhibit
HDAC activity following activation and release of the HDACi PBA was
measured in nuclear extracts of the cisplatin-sensitive and -resistant cell
lines (Fig. 4). An HDAC fluorimetric activity assay was used which is
the method of choice in the recent literature [20,24,27,50]. A2780 and
A2780cis cells were incubated with IC50 doses (Tables 1, 24 h time-
point) of A – C for 24 h. Cisplatin, the free ligand PBA and the known
HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) were used as
controls. All treated cells showed reduced HDAC activity. B and C had
the strongest effect on HDAC activity and are more potent HDAC in-
hibitors than SAHA. The decrease in HDAC activity in A2780 and
A2780cis cells treated with cisplatin is noteworthy, as this is in contrast
to the study by Raveendran et al. who observed no HDAC inhibitory
activity in MCF-7 cells exposed to cisplatin [27].
Fig. 2. (a) Cellular uptake of cisplatin and complexes A – D into A2780 cells. (b) DNA platination in A2780 cells incubated with cisplatin and complexes A – D. A2780
cells were incubated for 24 h with IC50 doses of the compounds (24 h concentrations according to Table 1). Error bars represent standard deviations from three
independent measurements.
Fig. 3. Fluorescent detection of ROS using H2DCFDA in A2780 and A2780cis cells after exposure to different concentrations of complex C over a period of 2 h. H2O2
(10 μM) was used as a positive control. Error bars represent standard deviations of three independent measurements.
Fig. 4. HDAC activity measured in nuclear extracts of A2780 and A2780cis cells
after exposure to IC50 concentrations of A – C, cisplatin, PBA and SAHA. The
IC50 concentrations of A – C and cisplatin are given in Table 1 (24 h timepoint).
IC50 (24 h) of PBA = 1945 μM (A2780) and 2076 μM (A2780cis). IC50 (24 h) of
SAHA = 30.2 μM (A2780) and 60.8 μM (A2780cis). Error bars represent
standard deviations of three replicates.
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3.6. DNA damage studies by immuno-detection of γ-H2AX foci
DNA damage induced by the coordination of cisplatin to the N7
position of guanine bases and the formation of cisplatin-DNA cross-links
triggers various cellular mechanisms such as cell cycle arrest, activation
of repair mechanisms, and cell death pathways [1,51]. When the DNA
damage leads to double strand breaks (DSBs), Ser-139 of the histone
H2AX is rapidly phosphorylated at the site of the DSB resulting in the
formation of discrete foci. The γ-H2AX foci can be detected and quan-
tified by immunofluorescence [52–54]. The number of γ-H2AX foci is
directly proportional to the DSBs and is an indicator of DNA repair
efficacy. H2AX phosphorylation has been observed on treatment with
cisplatin [55,56]. It is believed that the phosphorylation of H2AX plays
a crucial role in the detection of DNA damage and in the activation of
DNA repair pathways.
The immunofluorescence microscopy images of A2780 and
A2780cis cells incubated with IC50 doses of complexes A – C for 24 and
48 h are depicted in Fig. 5. The formation of γ-H2AX foci is clearly
visible. The images of cells treated with cisplatin and PBA are also
shown for comparison.
γ-H2AX foci generation after 24 and 48 h exposure to IC50 con-
centrations of A – C, cisplatin and PBA was determined quantitatively
by flow cytometry (Fig. 6). Compared to the untreated control, a sig-
nificant increase in γ-H2AX foci was observed in A2780 cells treated
with PBA, cisplatin, A, B, and C with the strongest response being eli-
cited by B. Cells treated with the most potent complex C also show
significant more DNA damage than cells treated with cisplatin. It has
been reported that resistance towards cisplatin in A2780cis cells is
caused by increased glutathione levels, enhanced DNA damage repair
and/or enhanced DNA damage tolerance [57]. After 48 h, some de-
crease in γ-H2AX foci is observed in A2780 cells exposed to B and
cisplatin indicating DNA repair. Overall, there is more DNA damage
repair in the resistant A2780cis cells compared to the sensitive cell line
as expected (Fig. 6b).
3.7. Apoptosis
The induction of apoptosis in A2780 and A2780cis cells treated with
A, B, C, cisplatin and PBA was studied using double staining with an-
nexin V/propidium iodide (AV/PI) and flow cytometry (Fig. 7). Double
staining allows for viable cells (AV-/PI-) to be distinguished in early
apoptosis (AV+/PI-), late apoptosis (AV+/PI+) and necrosis (AV-/PI
+). Treatment of A2780 and A2780cis cells with IC50 concentrations of
the Pt(IV) complexes resulted in a significant percentage of late apop-
totic cells after 24 h. The percentage of cells in late apoptosis are in the
order C > A > cisplatin> B> > PBA and is similar in both cell
lines. The percentage of late apoptotic cells decreases after 48 h. The
observation that complex C leads to the highest percentage of late
apoptotic cells correlates with its low IC50 value. Unlike cisplatin, for
which a clear difference in the percentage of late apoptotic A2780 and
A2780cis cells is observed, a similarly high percentage of cells of both
cell lines enter the late apoptotic state on exposure to complex C con-
firming that the Pt(IV) complex is less discriminative, in line with its
resistance factor value of 1.4. Apparently, the mechanism of cisplatin-
resistance in A2780cis cells does not interfere with the ability of C to
elicit its cytotoxic effect after activation and release of PBA and cis-
platin. Cellular responses to ROS and apoptosis are linked to the mi-
tochondria which are involved in the resistance mechanism of A2780cis
cells [58]. A recent in-depth mechanistic study has shown that the
apoptosis and mitochondria-related gene expression profiles of
A2780cis cells after exposure to Cu diimine complexes contrast with the
response of A2780 cells [59]. Similar investigations using the Pt PBA
complexes will be of interest for future work.
Fig. 5. A2780 and A2780cis cells exposed to IC50 concentrations of complexes A, B and C, cisplatin and PBA in comparison to the negative control. The IC50
concentrations of A – C and cisplatin are given in Table 1 (24 h timepoint). IC50 (24 h) of PBA = 1945 μM (A2780) and 2076 μM (A2780cis). γ-H2AX foci were
visualized using primary antibody staining with fluorescent FITC secondary label. Propidium iodide was used as a nuclear counter stain.
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4. Conclusions
The monosubstituted complex cis,cis,trans-[Pt(NH3)2Cl2(PBA)(OH)],
the symmetrically disubstituted complex cis,cis,trans-[Pt(NH3)2Cl2(PBA)2]
and the unsymmetrically disubstituted complex cis,cis,trans-[Pt
(NH3)2Cl2(PBA)(Bz)] overcome cisplatin resistance, are more cytotoxic in
A2780 and A2780cis ovarian cancer cells than cisplatin and induce cell
death pathways leading to apoptosis in both cell lines.
While our study confirms that the three Pt(IV) complexes interact
with their intended targets, DNA and HDAC, it has to be kept in mind
that their mode(s) of action may be more complex. PBA is also known to






























































Fig. 6. Immuno-detection of γ-H2AX foci post exposures in (a) A2780 and (b) A2780cis cells treated with IC50 doses of complexes A – C, cisplatin and PBA. The IC50
concentrations of A – C and cisplatin are given in Table 1 (24 h timepoint). IC50 (24 h) of PBA = 1945 μM (A2780) and 2076 μM (A2780cis). Error bars represent
standard deviations of three independent measurements.
Fig. 7. Annexin V/PI staining and flow cytometry analysis of A2780 and A2780cis cells after 24 h (a, b) and after 48 h (c, d) exposure to IC50 concentrations of A, B,
C, cisplatin and PBA. The IC50 concentrations of A – C and cisplatin are given in Table 1 (24 h timepoint). IC50 (24 h) of PBA = 1945 μM (A2780) and 2076 μM
(A2780cis). Error bars represent standard deviations of three independent measurements.
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metabolizing enzymes [60] and to reverse the Warburg effect by in-
hibiting pyruvate dehydrogenase kinase [61]. The suggestion that many
Pt(IV) complexes with a bioactive axial ligand designed as dual-action
pro-drugs may in fact be multi-action pro-drugs was discussed in a re-
cent review article [62]. The ROS data seem to support a multimodal
mechanism for the PBA complexes. ROS play a role in the activation of
signalling pathways and transcription factors that induce cell death
processes including apoptosis. At concentrations close to its IC50 value
the most cytotoxic complex C leads to markedly increased cellular ROS
levels which can mediate apoptosis independent of DNA damage.
Consistently, the γ-H2AX foci generation data confirm that the Pt(IV)
PBA complexes kill cancer cells only to a certain extent by DNA damage
and that DNA damage is only one of their cytotoxic effects.
In summary, cis,cis,trans-[Pt(NH3)2Cl2(PBA)(OH)], cis,cis,trans-[Pt
(NH3)2Cl2(PBA)2] and cis,cis,trans-[Pt(NH3)2Cl2(PBA)(Bz)] are potent
cytotoxins that act via multimodal mechanisms involving DNA damage
via γ-H2AX foci production and cell death mechanisms independent of
cisplatin resistance.
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